Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONAR: Atrasentan for Diabetic Nephropathy
NCT01858532Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2013
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of atrasentan in diabetic nephropathy (DN), sponsored by AbbVie Inc.. Started May 2013; status: terminated.
02
Drugs
atrasentan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01858532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01858532.